On August 17, 2022 NRG and Curium reported that they have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m) (Press release, Curium, AUG 17, 2022, View Source [SID1234618491]). Tc-99m is the most used isotope in nuclear medicine for diagnosing life-threatening diseases, such as cardiovascular diseases, lung and brain disorders and cancer. With this renewed collaboration 30,000 patients a day can continue to rely on the Petten nuclear medicine manufacturing capabilities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Every year, some 49 million treatments are carried out on patients with nuclear medicines, and Tc-99m is used in more than 80% of these examinations. Both NRG and Curium are market leaders and therefore important links in the supply chain of Tc-99m. NRG uses its High Flux Reactor (HFR) to produce the isotopes, which Curium then uses for its nuclear medicine products for the benefit of the patients.

Vinod Ramnandandal, CCO NRG PALLAS commented: "With this renewed collaboration we are taking a big step towards meeting the continuing demand and confirming our ongoing partnership. This is also particularly good news for the doctors and patients who need the isotopes."

Frank de Lange, Managing Director Curium Netherlands commented: " This multi-year agreement confirms our commitment to doctors and patients worldwide building on our trusted legacy in nuclear medicine."